- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:00 | ImageneBio, Inc. GAAP EPS of -$2.91 | 1 | Seeking Alpha | ||
| 14:13 | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 13:18 | ImageneBio, Inc.: ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team | 173 | GlobeNewswire (Europe) | $142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to... ► Artikel lesen | |
| 12:31 | ImageneBio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.10. | ImageneBio ernennt CEO Kristin Yarema zur Interims-Finanzchefin | 2 | Investing.com Deutsch | ||
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 22.10. | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.10. | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | ImageneBio files to sell 2.51M shares of common stock for holders | 2 | Seeking Alpha | ||
| 08.09. | ImageneBio, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.08. | ImageneBio, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 01.08. | ImageneBio: Vorstand genehmigt Anreizplan 2025 zur Mitarbeitergewinnung | 2 | Investing.com Deutsch | ||
| 01.08. | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 134 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and... ► Artikel lesen | |
| 29.07. | ImageneBio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.07. | Ikena Oncology, Inc.: Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million | 257 | GlobeNewswire (Europe) | The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will... ► Artikel lesen | |
| 24.07. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 23.07. | Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company | 1 | Investing.com | ||
| 23.07. | Ikena Oncology, Inmagene Biopharmaceuticals appoint Kristin Yarema, as CEO | 1 | Seeking Alpha | ||
| 23.07. | Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm | 5 | Investing.com | ||
| 23.07. | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company | 251 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,380 | +5,37 % | DAX-Check LIVE: BMW, Auto1 Group, Evotec, Fresenius, Kontron, Siemens Healthineers, Vonovia | Nach dem freundlichen Auftakt in den Börsenmonat November geriet der DAX gestern deutlich unter Druck. Zwischenzeitlich rutschte der Leitindex im Tagestief um rund zwei Prozent ab. Auf dem niedrigeren... ► Artikel lesen | |
| BIOGEN | 138,00 | +0,15 % | Biogen auf der Wedbush ASN 2025: Neue Strategien für die Nierentherapie Felzartamab | ||
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| MAINZ BIOMED | 1,500 | +21,95 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed nimmt an der 38. Jahrestagung der Gastroenterologischen Arbeitsgemeinschaft Rheinland-Pfalz (GARPS) teil | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Konferenz
Mainz Biomed nimmt an der 38. Jahrestagung der Gastroenterologischen Arbeitsgemeinschaft Rheinland-Pfalz (GARPS)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 35,045 | 0,00 % | Here's Why Shares in Viking Therapeutics Shot Higher in October | ||
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| GALAPAGOS NV | 28,240 | -0,42 % | Galapagos NV: Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update | Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,700 | +2,78 % | Earnings Outlook For Cellectar Biosciences | ||
| CARDIFF ONCOLOGY | 1,988 | +0,30 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,126 | -3,80 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 9,490 | 0,00 % | Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value | BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics... ► Artikel lesen | |
| CYTOKINETICS | 57,00 | -0,87 % | Cytokinetics, Incorporated: Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 | Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov.... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,724 | +4,78 % | CytomX Therapeutics stock price target raised to $6.50 at Piper Sandler | ||
| SPERO THERAPEUTICS | 2,290 | +1,10 % | Insights Ahead: Spero Therapeutics' Quarterly Earnings | ||
| PERSONALIS | 7,825 | +7,34 % | Personalis stock jumps 28% on Medicare coverage for cancer test |
Das Unternehmen IMAGENEBIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,140 (-1,61 %) liegt der Kurs bei 8,550 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.